X

HCP Login

By logging in to our website you will have full access to its content, including Healthcare Professional resources. Click here to register or login below.

X

Register your interest

Complete this form to register your interest for this meeting and we will get back to you.

Indicates required fields.

X

Reporting Adverse Events

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. In the Republic of Ireland information can be found at http://www.hpra.ie. Adverse events should also be reported to Merck Serono Limited - Tel: +44(0)20 8818 7373 or email: medinfo.uk@merckgroup.com.

X

Welcome to Merck Neurology

You may request sponsorship to attend a Merck organised meeting. Merck is committed to supporting the professional development and clinical education of healthcare professionals in MS.

Your request for sponsorship will be reviewed by the Merck Medical team. Upon receipt of your request we will email you within a week to advise timelines for the review of your request. Subject to sponsorship being granted, you will be required to sign a sponsorship agreement.

Indicates required fields.

X

Browser Local Storage Cleared

Your local storage for MerckNeurology.co.uk has been cleared. If you continue to use this website we may continue utilise your browsers local storage.

Dosing calculator

  • The recommended dose of MAVENCLAD® is 3.5 mg/kg over 2 years, given in two treatment courses of 1.75 mg/kg/year
  • Each treatment course consists of two treatment weeks (week 1 and week 5), each of 4 or 5 days’ oral therapy

Use the calculator below to find out the correct dosing schedule for your patients.

MAVENCLAD® 10 mg tablets are not scored.

Please enter your patient's weight:

Please only enter numbers up to one decimal place

MAVENCLAD comes in pack sizes of 1, 4 and 6 tablets.

Week 1 pill pill Week 5
Day 1 1 1 Day 1
Day 2 1 1 Day 2
Day 3 1 1 Day 3
Day 4 1 1 Day 4
Day 5 0 0 Day 5

Total number of tablets required
(each year)

8
Use of MAVENCLAD in patients weighing less than 40kg has not been investigated. Please enter a value ≥40kg.
No Dosing Found...

MAVENCLAD® treatment in MS with a weight-based tailored dosing regimen1

Dose of MAVENCLAD® per treatment week by patient weight in each treatment year 1

Mode of administration1

  • The tablets must be taken with water, and swallowed without chewing
  • As the tablets are uncoated, they must be swallowed immediately once removed from the blister and not be left exposed on surfaces or handled for any period of time greater than that required for dosing
  • If a tablet is left on a surface, or if a broken or fragmented tablet is released from the blister, the area must be thoroughly washed.
  • The patient’s hands must be dry when handling the tablets and washed thoroughly afterwards
  • The tablets can be taken independent of food intake. However, it is recommended that administration of any other oral medicinal product be separated from that of MAVENCLAD® by at least 3 hours

Missed dose

  • Advise patient to take their MAVENCLAD® as soon as they remember if on the same day as the missed dose
  • If this is the next day, the treatment course should be extended by the number of days in that treatment week
  • Take no more than the recommended daily dose on any single day. A missed dose must not be taken together with the
    next scheduled dose on the following day. In the case of a missed dose, the dosing period should be extended

Please refer to the prescribing information or the Summary of Product Characteristics (SPC) for a full list of contraindications, special warnings and precautions

Patients can be referred to the patient information leaflet (PIL) if necessary

 

VIEW REFERENCES

1. MAVENCLAD® Summary of Product Characteristics. Merck.
2. Giovannoni G, et al. N Engl J Med. 2010;362:416–26.
3. Giovannoni G, et al. N Engl J Med. 2010;362:416–26 (Supplementary information).
4. Giovannoni G, et al. Mult Scler. 2018;24:1594–1604.
5. Data on file CLAD005
6. Montalban X, et al. AAN. 2016;[P3.029].
7. Leist TP, et al. Lancet Neurol. 2014;13:257–67.
8. PREMIERE Clinical trials registry. Available at: https://clinicaltrials.gov/ct2/show/NCT01013350 [Accessed 19th November 2018].
9. Baker D, et al. Neurol Neuroimmunol Neuroinflamm. 2017;4:e360.
10. Soelberg-Sørensen P, et al. ENS. 2009;[P359].
11. Soelberg-Sørensen P, et al. ENS. 2010;[P442].
12. Giovannoni G. Neurotherapeutics. 2017;14:874-7.
13. Giovannoni G. Curr Opin Neurol. 2018;31:233–43.
14. Scolding N, et al. Pract Neurol. 2015;15:273–9.
15. Cook S, et al. AAN. 2016;[P3.058].
16. Giovannoni G, et al. Lancet Neurol. 2011;10:329–37.
17. Giovannoni G, et al. Mult Scler. 2018;doi: 10.1177/1352458518771875.
18. Giovannoni G, et al. ECTRIMS. 2017;[P1143].
19. Alemtuzumab Summary of Product Characteristics. Sanofi Genzyme.
20. Natalizumab Summary of Product Characteristics. Biogen.
21. Ocrelizumab Summary of Product Characteristics. Roche.
22. Cook S, et al. EAN. 2017;[P0543].
23. Cook S, et al. Mult Scler. 2011;17:578–93.
24. Cook S, et al. ECTRIMS-ACTRIMS. 2017;[P1142].
25. Galazka A, et al. ECTRIMS-ACTRIMS. 2017;[P1878].
26. MAVENCLAD® European Public Assessment Report, September 2017.
27. Soelberg-Sørensen P, et al. EAN. 2017;[EP3120]
28. Data on File, CLAD001 – Incidence of Lymphopenia, June 2018.
29. Pakpoor J, et al. Neurol Neuroimmunol Neuroinflamm. 2015;2:e158.
30. Stuve O, et al. ECTRIMS. 2017;[P690].
31. Soelberg-Sørensen P, et al. ECTRIMS. 2017;[P1141].
32. Cvetanovich GL, Hafler DA. Curr Opin Immunol. 2010;22:753–60.
33. Ceronie B, et al. J Neurol. 2018;265:1199–1209.
34. Leist TP, et al. Clin Neuropharmacol. 2011;34:28–35.
35. Giovanni G, et al. Mult Scler. 2017; doi:10.1177/1352458517727603.
36. Giovanni G, et al. EAN. 2017; [PO542].
37. Giovanni G, et al. ECTRIMS. 2016.

This website is intended for Healthcare Professionals in the United Kingdom and Ireland. To access prescribing information for Merck Neurology medicines please click here.

UK&IE/CLA/0519/0045(1)a - September 2019

© 2017 Merck Serono Ltd.Registered Address: Merck Serono Ltd. 5 New Square, Bedfont Lakes Business Park, Feltham, TW14 8HA, United Kingdom
Merck Ltd (Ireland), 4045 Kingswood Rd, Citywest Business Park, Dublin 24, Ireland.
Tel: +44 (0) 20 8818 7373 | Email: medinfo.uk@merckgroup.com
A company registered in England and Wales. Company Registration Number: 00990823

Reporting Adverse Events
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. In the Republic of Ireland information can be found at www.hpra.ie. Adverse events should also be reported to Merck Serono Limited – Tel: +44(0)20 8818 7373 or email: medinfo.uk@merckgroup.com.